Rocket Pharmaceuticals Inc
RCKT
Get informed when a big investor buys or sells
+ FollowMarket Cap$421.49M
Close$
$0.47
87.7% downside
Current Fair Value
87.7% downsideOvervalued by 87.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $421.49 Million |
|---|---|
| Enterprise Value | $221.78 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.01 |
| Beta | 0.47 |
| Outstanding Shares | 112,844,880 |
Return
| Return on Equity | -4.68% |
|---|---|
| Return on Assets | -4.08% |
| Return on Invested Capital | -1.96% |
Valuation & Multiples
| P/E Ratio | -24.13 |
|---|---|
| PEG | 8.65 |
| Price to Sales | - |
| Price to Book Ratio | 1.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -28.88 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$0.86
Average shareholder expectationRevenue Estimate
$18.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$222,222
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0747▼ 36.04% |
|---|---|
| Total Calls | 384,200▲ 16.18% |
| Total Puts | 28,700▼ 80.06% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.59%▲ 2.91% |
|---|---|
| Total Invested | $344.61M▼ 0.93% |
| Investors Holding | 185▼ 20.00% |
ESG Score
No data
About Rocket Pharmaceuticals Inc
151 employees
CEO: Gaurav Shah